Heart failure & cardiomyopathies
Impact of Comorbidities on Health Status Measured Using the Kansas City Cardiomyopathy Questionnaire in Patients with Heart Failure with Reduced and Preserved Ejection Fraction
Authors' conclusion
Cardiac and non-cardiac comorbidities are common in both HFrEF and HFpEF patients and most are associated with reductions in health status although the impact varied among comorbidities, by the number of comorbidities, and by HF phenotype.
Study context
- Population
- Patients with HFrEF or HFpEF enrolled in the ATMOSPHERE, PARADIGM-HF, DAPA-HF, TOPCAT and PARAGON-HF trials
- Participants
- 20,159 vs 6,563
- Comparison
- Kansas City Cardiomyopathy Questionnaire (KCCQ) scores by comorbidity and heart failure (HF) phenotype
- HFrEFn = 20,159reference
- HFpEFn = 6,563
- Outcome
- KCCQ domain scores and overall summary score (KCCQ-OSS) across comorbidities
Methodological detailsATMOSPHERE, PARADIGM-HF, DAPA-HF (HFrEF), TOPCAT, PARAGON-HF (HFpEF)
- ATMOSPHERE, PARADIGM-HF, DAPA-HF (HFrEF)
- TOPCAT, PARAGON-HF (HFpEF)
Pooled result
As reported in the abstract
KCCQ-OSS
| Group | Value | KCCQ-OSS, 0 comorbidities | KCCQ-OSS, ≥4 comorbidities |
|---|---|---|---|
| HFrEF | 71.3 | 76.8 | 66.4 |
| HFpEF | 67.8 | 73.7 | 65.2 |
Value
HFrEF71.3
HFpEF67.8
KCCQ-OSS, 0 comorbidities
HFrEF76.8
HFpEF73.7
KCCQ-OSS, ≥4 comorbidities
HFrEF66.4
HFpEF65.2
Further pooled results
Comorbidity prevalence
AF
CKD
Diabetes
Obesity
Angina
COPD
Stroke
Anaemia
Original publication
Impact of Comorbidities on Health Status Measured Using the Kansas City Cardiomyopathy Questionnaire in Patients with Heart Failure with Reduced and Preserved Ejection Fraction. Eur J Heart Fail. Published 3 August 2023. doi:10.
Summarised from the published abstract; every number is checked against it